

MOLECULAR DETECTION OF MULTI-DRUG RESISTANT *P. AERUGINOSA* ISOLATED FROM NEONATAL INFECTIONS

AMAL TALIB ATIYAH AL-SA'ADY¹ & NAHER H. S²

¹Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Hillah, Iraq

²Department of Microbiology, College of Medicine, University of Babylon, Hillah, Iraq

ABSTRACT

Throughout this study, multi-drug resistant *P. aeruginosa* was isolated from neonatal infections in order to detect the genes being responsible of antibiotic resistance in these bacteria by molecular technique (PCR). Antibiotic sensitivity test results demonstrated that *P. aeruginosa* have (100%) resistance against each Carbenicillin, Amoxycylave, Cephalothin and Rifampicin, and high level resistance $\geq 70\%$ for most other antibiotics. While 0% resistance (100% sensitivity) was shown against each IPM, MRP. The results of minimum inhibitory concentration, MIC, by using HiComb test showed that *P. aeruginosa* has 100% resistance for Amoxycylave (4-240 $\mu\text{g/ml}$), 70% for Cloramphenicol (4-120 $\mu\text{g/ml}$), 60% for Cefepem (16-128 $\mu\text{g/ml}$), 50% for Ciprofloxacin (0.5-120 $\mu\text{g/ml}$), 30% for Amikacin (0.032-128 $\mu\text{g/ml}$), 20% for Piperacillin (5-120 $\mu\text{g/ml}$) and 10% for Ceftazidime (8-64 $\mu\text{g/ml}$). PCR results demonstrated that among 35 isolates of *P. aeruginosa*, highest incidence 51.4% have *arr-2* gene followed by 49% have *aac(3)I* and 37% have *bla*^{bla} CARB.

KEYWORDS: Neonates, Infections, Multi-Drug Resistant *P. aeruginosa*

INTRODUCTION

P. aeruginosa represents an unusual phenomenon of antimicrobial resistance among prokaryotes since practically all known mechanisms of resistance be found in this organism including decreased outer membrane permeability, pincillin binding protein modification, increased expression of efflux pumps system, alginate and enzymatic inactivation of antibiotics¹. These various mechanisms of resistance in *P. aeruginosa* often lead to cross-resistance among different antimicrobial classes resulting in multidrug-resistant *P. aeruginosa* strains were first reported in patients with cystic fibrosis² and rendering many currently available antipseudomonal antimicrobials ineffective³. Nosocomially *P. aeruginosa* showed high resistance to disinfectants and antiseptics used in the hospital leading to wound and hospital contamination. On the other hand, this organism has an extraordinary capacity for the development of antimicrobial resistance to virtually all antipseudomonal agents through the selection of mutations in chromosomal genes leading to the conferring resistance to penicillins, cephalosporins and fluoroquinolones, in addition to the determining resistance to carbapenems, so, intrinsic and acquired resistance makes *P. aeruginosa* as one of the most difficult organisms to be treated and eradicated^{4,5}. Some other studies have reported that, the acquisition of resistant strains to ceftazidime, imipenem, piperacillin, or ciprofloxacin is significantly associated with longer hospital stay and an increased rate of secondary bacteremia with *P. aeruginosa* infection².

Although forethrmore it is sensitive to some antibiotics, e. g. ceftazidime, imipenem, ciprofloxacin and ofloxacin, but resistance to these antibiotics has also emerged^{6,7}.

Rifampin is derived from rifamycin which inhibits bacterial DNA-dependent trna synthesis by inhibiting bacterial

DNA-dependent RNA polymerase. *arr-2* gene was responsible of rifampin resistance in *P. aeruginosa* and it is located on a gene cassette within a class I integron. Resistance to rifampicin arises from mutations that alter residues of the rifampicin binding site on RNA polymerase, resulting in decreased affinity for rifampicin^{8,9}.

Gentamicin is an aminoglycoside antibiotic, it is used to treat many types of bacterial infections, particularly those caused by gram-negative rods and *Staphylococci*. The mechanism of gentamicin action represents by irreversibly binding the 30S subunit of the bacterial ribosome, interrupting protein synthesis¹⁰. *aac(3)I* gene determines resistance to gentamicin¹.

Carbenicillin is a bacteriolytic antibiotic belonging to the carboxypenicillin subgroup of the penicillins. It has gram-negative coverage but limited gram-positive coverage. The carboxypenicillins are susceptible to degradation by beta-lactamase enzymes, four types of carbenicillin hydrolysing b-lactamases of *Pseudomonas* specific enzyme (PSE or CARB) were found in *P. aeruginosa* which include PSE-1(CARB-2), PSE-4(CARB-1), CARB-3 and CARB-4. *bla*_{CARB} gene determines resistance to Carbenicillin¹¹.

MATERIALS AND METHODS

During a period of March (2012) to February (2013), a total of 666 samples were collected from neonates, mothers and environment in Babylon Hospital for Pediatric and Gynecology in Hilla \Iraq. Those samples included blood, urine, CSF and swabs (oral cavity, umbilical cord, skin, eye, respiratory secretions, nose and surgical site) from neonates. While samples from mothers included amniotic fluid from mothers in delivery room, umbilical cord blood from recent neonate (cord blood) and HVS from pregnant women. Finally, samples from environment included swabs from mask of mechanical ventilator, cannula, nursery, curtage unit, disinfectant, fluid sucker, catheter, floor and stage of delivery room. Bacterial isolates were investigated for identification according to their characteristics and compared with referential references,^{12, 13, 14}.

Antimicrobial Susceptibility

Disc Diffusion Test was performed according to Bauer¹⁵ method on by using 27 antibiotic discs. The antibiotic discs were placed on an inoculated Muller-Hinton agar plate and incubation at 37°C for 18-24 hrs. Then, inhibition zone was measured and compared to standard criteria in CLSI¹⁶

Minimum Inhibitory Concentration (MIC) by HiComb Test: the HiComb strip was applied to an inoculated Muller-Hinton agar plate and was incubated at 37°C for 18-24 hrs. After incubation an ellipse will appear, that intersects the MIC value scale (in µg/ml) the lowest concentration that will inhibit the growth of a test organism as determined visually by the lack of turbidity over a defined interval related to an organism's growth rate, most commonly after 18 to 24 hrs^{17,18}.

Moleculer Assays: Polymerase Chain Reaction (PCR) were performed for detection the responsible genes of antibiotic resistance which included *bla*_{CARB}, *aac(3)I* and *arr-2* in multi-drugs resistant *P. aeruginosa* by using the primers and PCR conditions which detailed in table 1.

Table 1: Primers Sequences and PCR Conditions for Multi-Drugs Resistant *P. aeruginosa*

Genes	Primer Sequence (5' → 3')	Product Size bp	PCR Cycle Program	References
<i>bla_{CARB}</i>	F: 5' - AAA GCA GAT CTT GTG ACC TAT TC-3' R: 5' - TCA GCG CGA CTG TGA TGT ATA AAC-3'	588	94°C 5min 1x	Wang <i>et al.</i> (2006)
			94°C 1min	
			55°C 1min 40x	
			72°C 1min	
<i>aac(3)I</i>	F: 5' -ACC TAC TCC CAA CAT CAG CC -3' 5' -ATA TAG ATC TCA CTA CGC GC- 3' R:	169	72°C 7min 1x	Shervington <i>et al.</i> (2001)
			95°C 3min 1x	
			95°C 30sec	
			60°C 45sec 40x	
<i>arr-2</i>	F: 5'- GCG TGC CTT GTT TCC ACA TT- 3' R: 5'- TCA CAC GCC CCA TAA AAC GA - 3'	466	72°C 2min	Designed for this study
			72°C 5min 1x	
			94°C 5min 1x	
			94°C 30sec	
			55°C 30sec 40x	
			72°C 30sec	
			72°C 5min 1x	

RESULTS AND DISCUSSIONS

A total of 510 bacterial isolates were identified from different samples revealed positive results for bacterial culture. Among 510 bacterial isolates, *P. aeruginosa* accounted 48(9.41%).

Antimicrobial Susceptibility

Disc Diffusion Test: The percentages of antibiotic resistance in *P. aeruginosa* are shown in table 2. Based on these data, this bacterium has fully sensitivity (100%) against each of IPM, MRP which can be attributed to the fact that β -lactam rings of these antibiotics are resistant to hydrolysis by most β -lactamases¹⁹. However, the result was in accordance with those results being reported by^{20, 21}.

Table 2: Percentages of Antibiotic Resistance in *P. aeruginosa* Isolates in this Study

Antibiotic	PIP	CB	AMC	KF	CPM	CTR	CTX	CAZ	IMP	MRP	AT	GEN	AK	TOB	TE	CIP	NX	NA	C	RIF
Resistance %	60	100	100	100	90	83	85	31	0.0	0.0	90	96	42	77	75	60	60	85	90	100

PIP=Piperacillin;CB=Carbencillin;;AMC=Amoxiclave;KF=Cephalothin;CPM=Cefepime;CTR=Ceftriaxone;CTX=Cefotaxime;CAZ=Ceftazidime;IMP=Imepenem;MRP=Meropenem;AT=Aztreonam;GEN=Gentamycin;AK=Amikacin;TOB=Tobramycin;TE=Tetracycline;CIP=Ciprofloxacin;NX=Norfloxacin;NA=Nalidixicacid;C=Chloramphenicol;RIF=Rifampicin.

In the present study, *P. aeruginosa* have fully resistance (100%) for each CB, AMC, KF and RIF, and high level resistance for other antibiotics: 96%(GEN), 90%(C), 90%(AT), 85%(CTX), 85%(NA), 83%(CTR), 77%(TOB), 75% (TE) and 60% (PIP). This result was in accordance with those results being reported by^{22,4} where referred that, *P. aeruginosa* showed a high resistance to most β -lactame antibiotics and cephalosporins. In addition, Strateva²³ pointed out that most *P. aeruginosa* was resistant to carbencillin. Resistance to β -lactams commonly results from drug inactivation by β -lactamases, drug extrusion through efflux pumps, changes in outer membrane permeability, and modification of PBP²⁴. Development of antibiotic resistance in Iraq is often related to the availability of antibiotics out of hospitals which encourage self-medication⁴.

Minimum Inhibitory Concentration (MIC) TEST: MIC is the lowest concentration of antibiotic that prevents growth of a given organism. The present study used MIC method for testing the susceptibility of *P. aeruginosa* and MIC values were based on break point recommended by CLSI¹⁶ for estimation of the response. Seven antibiotics (CAZ, AK,

CIP, C, CPM, AMC, PIP) against 10 isolates of *P.aeruginosa*. MIC values for the studied antibiotics were detailed in table 3.

As detailed in table 3, the percentages of resistant *P.aeruginosa* isolates for antibiotics according to the MIC values were 10%CAZ(8-64 µg/ml), 30%AK(0.032-128 µg/ml), 50%CIP(0.5-120 µg/ml), 70%C(4-120 µg/ml), 60%CPM(16-128 µg/ml), 100%AMC(4-240 µg/ml) and 20%PIP(5-120 µg/ml). This results partially related with arecent study by⁽⁴⁾ who reported that resistant rate of same bacteria for amikacin and ciprofloxacin was 30% (0.05-256 µg/ml) and 40%(0.004-60 µg/ml) respectively. This variation may be attributed to that the researchers depend on breakpoints recommended by various international committees which recommended variable values of breakpoints²⁵.

Table 3: The Values of Minimum Inhibitory Concentration (MIC) for Some Antibiotics against *P. aeruginosa* Isolated in this Study

Antibiotics	CAZ 0.016-256	AK 0.001- 256	CIP 0.001- 240	C 0.001-240	CPM 0.001-240	AMC 0.001-240	PIP 0.001-240
Standard values ≤SIR>	8 16 32	16 32 64	1 2 4	4 8 16	8 16 32	4 _ 8	64 _128
MIC ranges µg/ml	8-64	0.032-128	0.5-120	4-120	16-128	4-240	5-120
Percentage of resistant bacteria	10%	30%	50%	70%	60%	100%	20%

Molecular Assays: In the present study, the molecular experiments using PCR assay emphasized on detection of three genes being responsible of resistance for three antibiotics as indicated in table 4. It is found that among 35 isolates of *P. aeruginosa*, highest incidence was 18(51.4%) for *arr-2* gene followed by 17(48.6%) *aac(3)I* and 13(37.1%) *bla*^{CARB}, table 4. The distribution of these genes varied in respect to the isolation source.

Table 4: Distribution and Percentages of Responsible Genes of Antibiotic Rasistance in *P. aeruginosa* Isolated in this Study

Gene The Source	<i>aac(3)I</i>	<i>bla</i> ^{CARB}	<i>arr-2</i>
Blood	2(11.7%)	2(15.4%)	2(11%)
Oral Cavity swab	6(35.3%)	5(38.4%)	6(33.3%)
Urin	1(5.9%)	1(7.7%)	1(5.6%)
CSF	1(5.9%)	---	---
Umbilical Cord swab	1(5.9%)	1(7.7%)	1(5.6%)
Skin swab	1(5.9%)	1(7.7%)	1(5.6%)
Respirotary Secretions swab	2(11.7%)	2(15.4%)	2(11%)
Surgical Sites swab	1(5.9%)	---	---
Cannula	---	---	1(5.6%)
Caesarian Section	1(5.9%)	---	1(5.6%)
Floor of Delivery Room	---	---	1(5.6%)
Disinfectant	1(5.9%)	1(7.7%)	1(5.6%)
Catheter	---	---	1(5.6%)
Total	17(48.6%)	13(37.1%)	18(51.4%)
Total Number of Isolates	35	35	35

The molecular detection of *arr-2* gene, which responsible of rifampicin resistance, revealed positive amplification with product size accounted 466 bp, as shown in figure 1. And it was distributed as detailed in table 4. The highest spread

of it was found among isolates from oral cavity 6(33.3%). This finding was in agreement with other studies; where reported that a new rifampin resistance gene, *arr-2*, has been found in *P. aeruginosa*²⁶ and the emergence of this gene in the American continent as gene cassettes from class I integrons²⁷.



Figure 1: Gel Electrophoresis of PCR Product of *Arr-2* Gene with Product Size= 466bp. The Isolates Numbered (3, 7, 8, 9) Were Positive For *Arr-2* Gene Whereas Isolates Numbered (1, 2, 4, 5, 6) Negative

The molecular detection of *aac(3)I* gene, which responsible of gentamicin resistance, revealed positive amplification with product size accounted for 169 bp, as shown in figure 2. *aac(3)I* gene was distributed as detailed in table 5. The highest frequency of it was recorded among isolates from oral cavity6 (35.3%). This finding was in agreement with other study who reported that *aac(3)I* gene is widespread among members of Enterobacteriaceae and other gram negative such as *Pseudomonas* and *Serratia* as well as *Acinetobacter*¹.




Figure 2: Gel Electrophoresis of PCR Product of *Aac(3)I* Gene with Product Size=169bp. The Isolates Numbered (3, 7, 8, 9) Were Positive for *Aac(3)I* Gene Whereas Isolates Numbered (1, 2, 4, 5, 6) Negative

The molecular detection of *bla*^{CARB} gene, which responsible of carbenicillin resistance, revealed positive amplification with product size accounted for 588 bp, as shown in figure 3. *bla*^{CARB} gene was distributed as detailed in table 5. The highest frequency was found among isolates from oral cavity 5(38.4%). This resistance may attribute to the fact that Carbenicillin is a bacteriolytic antibiotic belonging to the carboxypenicillin subgroup of the penicillins which are susceptible to degradation by beta-lactamase enzymes¹¹




Figure 3: Gel Electrophoresis of PCR Product of *Bla carb* Gene with Product Size= 588bp. The Isolates Numbered (3, 6, 7, 8, 9) Were Positive for *Bla carb* Gene Whereas Isolates Numbered (1, 2, 4, 5) Negative

CONCLUSIONS

In light of the results documented in this study, one can conclude that multi-drug resistant *P. aeruginosa* isolated from neonatal infections harbore the genes which render the organisms to resist antibiotic in high rate.

REFERENCES

1. Strateva, T. and Yordanov, D. (2009). *Pseudomonas aeruginosa* a phenomenon of bacterial resistance. *J.Med.Microbiol.* 58(9):1133-1148.
2. Paramythiotou, E; Lucet,J; Timsit,J; Vanjak,D; Paugam-Burtz, C; *et. al.* (2004) Acquisition of Multidrug-Resistant *Pseudomonas aeruginosa* in Patients in Intensive Care Units: Role of Antibiotics with Antipseudomonal Activity.*Clin. Infect. Dis*; 38(5):670-677.
3. Bulik, C. C; Christensen, H. And Nicolau, D. P. (2010) In Vitro Potency of CXA-101, a novel cephalosporin, against *Pseudomonas aeruginosa* Displaying Various Resistance Phenotypes, Including Multidrug Resistance. *Antimicrob. Agents Chemother*; 54: 557-559.
4. Saleh, R. H. (2012) Immunological and molecular Study on *Pseudomonas aeruginosa* isolated from clinical samples in Babylon Province. PH.D. thesis. College of medicine. University of Babylon.
5. AL-Gibouri, L. F. H. (2006). The resistance of *Pseudomonas aeruginosa* isolated from clinical cases to antimicrobials. M.Sc.thesis in Microbiology. College of Medicine.Babylon Univ.
6. Sekiguchi, J; Asagi, T; Miyoshi-Akiyama, T; Kasai, A; Mizuguchi, Y; *et. al.* (2007) Outbreaks of Multidrug-Resistant *Pseudomonas aeruginosa* in Community Hospitals in Japan. *J. Clin. Microbiol*; 45(3): 979-989.
7. Plasencia, V; Borrell, N; Maciá, M. D; Moya, B; Pérez, J. L. and Oliver, A. (2007) Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. *Antimicrobial Agents Chemother.* 51(7): 257-258.
8. Campbell, E. A; Korzheva, N; Mustaev, A; Murakami, K; Nair, S; *et. al.* (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell* 104 (6): 901–12.
9. Feklistov, A; Mekler, V; Jiang, Q; Westblade, L. F; Irschik, H; *et. al.* (2008) Rifamycins donot function by allosteric modulation of binding of Mg^{2+} to the RNA polymerase active center. *Proc. Nati. Acad. Sci. U. S. A*; 105(39): 14820–14825.
10. Moulds, R. and Jeyasingham, M.(2010) Gentamicin: a great way to start. *Australian Prescriber* (33): 134–135.
11. Bert, F; Branger, C; Lambert-Zechovsky, N.(2002) Identification of PSE and OXA β -lactamase genes in *Pseudomonasaeruginosa* using PCR–restriction fragment length polymorphism. *J .Antimicrobial Chemotherapy*; 50: 11–18.
12. Baron, E. J; Peterson, L. R. and Finegold, S. M. (1994) Bailey and Scott's Diagnostic Microbiology. 9th ed. Mosby, Saint Louis, USA.

13. Collee, J. G; Fraser, A. G; Marmino, B. P. and Simons, A. (1996) Mackin and McCartney Practical Medical Microbiology. 14th ed., the Churchill Livingstone, Inc. USA.
14. MacFaddin, J. F. (2000) Biochemical tests for identification of medical bacteria. 3rd ed. Williams and Wilkins – Baltimor. PP: 321-400.
15. Bauer, A. W; Kirby, W. M; Sherris, J. C. and Turck, M. (1966) Antibiotic susceptibility testing by a standardized single disk method. *Amer. J. Clin. Pathol.* 45: 493-496.
16. Clinical and Laboratory Standards Institute (CLSI) (2012) Performance standards for antimicrobial susceptibility testing. Approved standard M100-S20. 32(3); National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Kingsbury, D. T. and Wagner, G. E.(1990)Microbiology, 2nded; HarwalPublishing, Pennsylvania, USA.pp:37–38.
18. Miller, L. A; Rittenhouse, S. F; Utrup, L. J. and Poupard, J. A.(1994) Comparison of three methods for determination of a single MIC of antimicrobial agent. *J. Clin. Microbiol*;32(5):1373–1375.
19. Al-Fu'adi, A. H. H.(2010)Phenotypic and Genotypic (*mecA* gene) of Methicillin Resistant *Staphylococcus aureus* (MRSA) Isolates in Dewaniya City. M. Sc thesis. Babylon University. College of medicine.
20. Watanabe, A; Takahashi, H; Kikuchi, T; Kobayashi, T; Gomi, K. *et. al.*(2000) Comparative *in vitro* activity of S-4661, a new parenteral carbapenems, and other antimicrobial agents against respiratory pathogens. *Antimicrob. Agents Chemother.*, 46:184-187.
21. Nomura, S. and Nagayama, A. (2002) *In vitro* antibacterial activity of S-4661, a new parenteral carbapenems, against urological pathogens isolated from patients with complicated urinary tract infections. *J. Chemother.*, 14(2):155-160.
22. Javiya, V. A. ; Ghatak, S. B; Patel, K. R. and Patel J. A. (2008) Antibiotic susceptibility patterns of *Pseudomonas aeruginosa* at a tertiary care hospital in Gujarat\India. *Indian .J. Pharmacol*; 40(5):230-234.
23. Strateva, T; Ouzounova-Raykova, V; Markova, B; Todorova, A; Marteva-Proevska, Y. & Mitov, I. (2007) Widespread detection of VEB-1-type extended spectrum b-lactamases among nosocomial ceftazidime-resistant *Pseudomonas aeruginosa* isolates in Sofia, Bulgaria. *J.Chemother*; 19,140-145.
24. Alvarez-Ortega, C; Wiegand, I; Olivares, J; Hancock, R. E. W. and Martínez, J. L. (2010) Genetic Determinants Involved in the Susceptibility of *Pseudomonas aeruginosa* to β -Lactam Antibiotics. *Antimicrob. Agents Chemother.* 54(10):4159-4167.
25. Al-Hassnawi, H. H.(2012)Molecular Characterization of Antibiotic Resistance and Virulence Factors of Methicillin Resistance *Staphylococcus aureus* (MRSA) Isolated from Clinical Cases in Babylon Province. PhD. thesis. College of Medicine. University of Babylon.
26. Tribuddharat, C and Fennewald, M.(1999) Integron-Mediated Rifampin Resistance in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*; 43(4): 960–962.
27. Fonseca, E; Freitas, F; Amorim, J; and Vicente, A. C. (2008) Detection of New *arr-4* and *arr-5* Gene Cassettes in Clinical *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* Strains from Brazil. *Antimicrobial agents and chemotherapy*; 52(5): 1865–1867.

